For biologic-experienced patients hospitalized with acute severe ulcerative colitis, off-label, high-intensity doses of tofacitinib (Xeljanz) given with intravenous corticosteroids may have reduced ...

When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab ...

Re-treatment with tofacitinib after a period of treatment interruption was well tolerated and effective in patients with ulcerative colitis who had shown a previous response to tofacitinib induction, ...

If you have a certain autoimmune condition, your doctor may recommend tofacitinib IR oral tablets. Autoimmune conditions cause your immune system to become overactive and attack your own body.

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the ...

Please provide your email address to receive an email when new articles are posted on . Tofacitinib demonstrated efficacy among older, biologic-naive patients. No major cardiovascular events were ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Human colon, illustration. Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure. For patients with ulcerative colitis (UC) ...

Favorable outcomes were observed among patients with vitiligo who received systemic Janus kinase inhibitors, with tofacitinib associated with the highest rate of complete resolution. Tofacitinib may ...

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers for full ...

The evaluation committee considered evidence submitted by Pfizer, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...